Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Steven Kelly, President and CEO, will represent the company at the conference on Tuesday, February 11 at 4:40 pm ET.
The presentation will be accessible via audio webcast through the Company's Investor Events section on their Investor Relations webpage, with -time archive availability following the event.
Carisma Therapeutics (Nasdaq: CARM), un pioniere nella sviluppo di terapie focalizzate sui macrofagi, ha annunciato la sua partecipazione alla prossima 35ª Conferenza Annuale sulle Scienze della Vita di Oppenheimer. Steven Kelly, Presidente e CEO, rappresenterà l'azienda alla conferenza martedì 11 febbraio alle 16:40 ET.
La presentazione sarà accessibile tramite audio webcast nella sezione Eventi per Investitori della pagina web delle Relazioni con gli Investitori dell'azienda, con la disponibilità di un archivio in tempo reale dopo l'evento.
Carisma Therapeutics (Nasdaq: CARM), un pionero en terapias centradas en macrófagos, ha anunciado su participación en la próxima 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. Steven Kelly, Presidente y CEO, representará a la compañía en la conferencia el martes 11 de febrero a las 4:40 p.m. ET.
La presentación será accesible a través de una transmisión de audio en su sección de Eventos para Inversores en la página de Relaciones con Inversores de la compañía, con disponibilidad de archivo en tiempo real tras el evento.
Carisma Therapeutics (Nasdaq: CARM), 대식세포 중심 치료 분야의 선구자로, 다가오는 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. Steven Kelly 사장 겸 CEO가 2월 11일 화요일 오후 4시 40분 ET에 컨퍼런스에서 회사를 대표합니다.
발표는 회사의 투자자 관계 웹 페이지의 투자자 이벤트 섹션을 통해 오디오 웨비나로 접근할 수 있으며, 이벤트 이후에는 실시간 아카이브도 제공됩니다.
Carisma Therapeutics (Nasdaq: CARM), un pionnier dans le domaine des thérapies ciblant les macrophages, a annoncé sa participation à la prochaine 35e Conférence Annuelle sur les Sciences de la Santé d'Oppenheimer. Steven Kelly, Président et CEO, représentera la société à la conférence le mardi 11 février à 16h40 ET.
La présentation sera accessible via un webinaire audio dans la section Événements pour Investisseurs de la page des Relations avec les Investisseurs de la société, avec une disponibilité d'archives en temps réel après l'événement.
Carisma Therapeutics (Nasdaq: CARM), ein Pionier in der makrophagenfokussierten Therapie, hat seine Teilnahme an der bevorstehenden 35. Jahrestagung der Oppenheimer Gesundheits- und Lebenswissenschaften angekündigt. Steven Kelly, Präsident und CEO, wird das Unternehmen am Dienstag, den 11. Februar um 16:40 Uhr ET vertreten.
Die Präsentation wird über eine Audio-Webcast in der Rubrik Investoren-Events auf der Investor-Relations-Webseite des Unternehmens zugänglich sein, mit Archivdiensten in Echtzeit nach der Veranstaltung.
- None.
- None.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.
Investors:
Shveta Dighe
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367990.html
SOURCE Carisma Therapeutics Inc.
FAQ
When is Carisma Therapeutics (CARM) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access Carisma Therapeutics' (CARM) Oppenheimer Conference presentation?
Who will represent CARM at the 2025 Oppenheimer Healthcare Conference?
What type of therapeutics does Carisma (CARM) specialize in?
